0001140361-24-002906.txt : 20240119
0001140361-24-002906.hdr.sgml : 20240119
20240119160619
ACCESSION NUMBER: 0001140361-24-002906
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240117
FILED AS OF DATE: 20240119
DATE AS OF CHANGE: 20240119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Colangelo Dominick
CENTRAL INDEX KEY: 0001313403
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35280
FILM NUMBER: 24545625
MAIL ADDRESS:
STREET 1: 1000 WINTER ST.
STREET 2: SUITE 2200
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vericel Corp
CENTRAL INDEX KEY: 0000887359
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943096597
STATE OF INCORPORATION: MI
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7349305555
MAIL ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC
DATE OF NAME CHANGE: 19960428
4
1
form4.xml
FORM 4
X0508
4
2024-01-17
0000887359
Vericel Corp
VCEL
0001313403
Colangelo Dominick
64 SIDNEY STREET
CAMBRIDGE
MA
02139
true
true
President and CEO
true
Common Stock
2024-01-17
4
M
0
16726
3.02
A
186711
D
Common Stock
2024-01-17
4
S
0
16726
37.97
D
169985
D
Common Stock
2024-01-18
4
M
0
16726
3.02
A
186711
D
Common Stock
2024-01-18
4
S
0
16726
38.58
D
169985
D
Stock Option (Right to Buy)
3.02
2024-01-17
4
M
0
16726
0
A
Common Stock
16726
366726
D
Stock Option (Right to Buy)
3.02
2024-01-18
4
M
0
16726
0
A
Common Stock
16726
350000
D
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 1, 2023.
These options, representing the right to purchase 440,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on April 5, 2015, which was one quarter after the date on which the option was granted.
These options, which were awarded on January 5, 2015, would otherwise expire and become forfeitable on January 5, 2025.
/s/ Sean Flynn, as Attorney-in-Fact for Dominick C. Colangelo
2024-01-19